IQVIA 報告第一季業績強勁，超乎分析師預期

IQVIA Holdings Inc. 公佈了 2024 年第一季強勁的財務業績，營收成長 2.9%，達到 37.37 億美元（不包括轉嫁，研發解決方案部門成長 6.9%）。該公司調整後每股收益為 2.54 美元，超出了分析師的預期，收入也超出了預期，達到 37.4 億美元。 IQVIA 的財務狀況仍然穩健，擁有 14 億美元的現金和等價物，並保持強勁的積壓訂單和訂單出貨比，顯示未來收入潛力強勁。

IQVIA Holdings Inc. Reports Solid Financial Performance in First Quarter of 2024

IQVIA Holdings Inc. 公佈 2024 年第一季穩健的財務業績

IQVIA Holdings Inc. (NYSE: IQV), a leading provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, has released its financial results for the first quarter of 2024, demonstrating continued strength and growth across its diverse service segments.

IQVIA Holdings Inc.（NYSE：IQV）是一家為生命科學行業提供先進分析、技術解決方案和臨床研究服務的領先提供商，該公司公佈了2024 年第一季的財務業績，展示了其多元化業務的持續實力和成長。

Revenue and Segment Performance

收入和部門表現

IQVIA reported total revenue of $3,737 million for the first quarter, representing a 2.3% increase on a reported basis and a 2.9% increase at constant currency compared to the same period in 2023. Notably, the Research & Development Solutions (R&DS) segment exhibited robust growth, with revenue increasing by 3.4% on a reported basis and 3.8% at constant currency. Excluding the impact of pass-throughs, the R&DS segment saw an impressive 6.9% growth on a reported basis.

IQVIA 報告第一季總營收為 37.37 億美元，與 2023 年同期相比，報告基礎上成長 2.3%，以固定匯率計算成長 2.9%。營收以報告計算成長3.4%，以固定匯率計算成長3.8%。據報告，排除轉嫁的影響，研發部門實現了 6.9% 的驚人成長。

The company's contracted backlog in R&DS reached $30.1 billion, representing a 7.9% year-over-year increase. Approximately $7.7 billion of this backlog is anticipated to convert to revenue within the next twelve months, indicating a strong pipeline for future growth. The first-quarter book-to-bill ratio was a favorable 1.23x, underscoring the company's ability to drive future revenue.

公司研發合約積壓金額達301億美元，較去年成長7.9%。其中約 77 億美元的積壓訂單預計將在未來 12 個月內轉化為收入，這表明未來成長的管道強勁。第一季的訂單出貨比為 1.23 倍，凸顯了該公司推動未來營收的能力。

Financial Position

財務狀況

IQVIA Holdings' financial position remained robust during the first quarter. As of March 31, 2024, the company held cash and cash equivalents totaling $1.4 billion. Net debt stood at $12.09 billion, resulting in a net leverage ratio of 3.38x trailing twelve-month Adjusted EBITDA.

IQVIA Holdings 第一季的財務狀況依然強勁。截至2024年3月31日，該公司持有現金及現金等價物總計14億美元。淨債務為 120.9 億美元，過去 12 個月的調整後 EBITDA 淨槓桿率為 3.38 倍。

The company generated an operating cash flow of $522 million and a free cash flow of $377 million for the first quarter. These positive cash flow metrics demonstrate IQVIA's financial health and ability to generate substantial cash flows, further solidifying its position as a leader in the life sciences industry.

該公司第一季營運現金流為 5.22 億美元，自由現金流為 3.77 億美元。這些積極的現金流量指標表明 IQVIA 的財務狀況良好，並且有能力產生大量現金流，進一步鞏固了其作為生命科學行業領導者的地位。

Earnings and Guidance

收益和指導

IQVIA surpassed analysts' expectations for both EPS and revenue in the first quarter. Adjusted diluted EPS came in at $2.54, slightly above the projected $2.48. Revenue of $3.74 billion comfortably exceeded the anticipated $3.7 billion, signaling stronger-than-expected top-line growth.

IQVIA 第一季每股收益和營收均超出分析師預期。調整後稀釋後每股收益為 2.54 美元，略高於預期的 2.48 美元。營收 37.4 億美元輕鬆超過預期的 37 億美元，顯示營收成長強於預期。

Despite the challenging global economic environment, IQVIA has reaffirmed its full-year 2024 guidance, expressing confidence in its business outlook. The company expects full-year revenue to range between $15.325 billion and $15.575 billion on a reported basis, factoring in the impact of currency fluctuations. This guidance implies a growth rate of 2.3 to 3.9%, with an estimated foreign exchange headwind of approximately 100 basis points.

儘管全球經濟環境充滿挑戰，IQVIA 仍重申了 2024 年全年指引，表達了對其業務前景的信心。考慮到貨幣波動的影響，該公司預計全年營收將在 153.25 億美元至 155.75 億美元之間。該指引意味著成長率為 2.3% 至 3.9%，預計外匯阻力約為 100 個基點。

IQVIA anticipates its full-year Adjusted EBITDA to be between $3,700 million and $3,800 million, representing a growth of 3.7 to 6.5%. The Adjusted Diluted EPS guidance is set at $10.95 to $11.25, indicating a year-over-year increase of 7.4 to 10.3%.

IQVIA 預計全年調整後 EBITDA 將在 37 億美元至 38 億美元之間，成長 3.7% 至 6.5%。調整後稀釋每股盈餘指引值為 10.95 美元至 11.25 美元，年增 7.4% 至 10.3%。

Conclusion

結論

IQVIA Holdings Inc.'s first-quarter financial performance highlights the company's operational resilience and the effectiveness of its business strategy. The solid growth in its R&DS segment, strong financial position, and positive cash flow generation underscore IQVIA's position as a leading provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company's reaffirmed guidance for the full year 2024 reflects its confidence in its ability to continue delivering value to its clients and stakeholders in the face of global uncertainties.

IQVIA Holdings Inc. 第一季的財務表現凸顯了該公司的營運彈性和業務策略的有效性。研發部門的穩健成長、強勁的財務狀況和正現金流的產生凸顯了 IQVIA 作為生命科學產業先進分析、技術解決方案和臨床研究服務領先提供者的地位。該公司重申的 2024 年全年指引反映了其在面對全球不確定性的情況下繼續為客戶和利害關係人提供價值的能力的信心。